Journal CHEST®
Specialist Dietary Intervention in Patients With Fibrotic Interstitial Lung Disease Experiencing Unintentional Weight Loss
By Rasleen Kahai, BSc, and colleagues
Unintentional weight loss in fibrotic interstitial lung disease (ILD) is a clinical red flag. It is multifactorial, reflecting disease burden, inactivity and inflammation, and antifibrotic gastrointestinal toxicity. It is also closely linked to frailty and worse quality of life. This single-center, pilot randomized controlled trial tested whether a 12-week, dietitian-led intervention is feasible and whether it shows a signal for benefit. The intervention included structured counseling, food fortification, and supplements when needed. The investigators randomized 40 of 128 screened patients in approximately seven months. They retained 100% of participants through 12 weeks.
The study was not powered for definitive efficacy. However, exploratory analyses suggested that the intervention may reverse the downward weight trajectory. More participants gained at least 1 kg. The modeled weight slopes diverged after approximately four weeks. Calorie intake improved; adjusted gastrointestinal symptom burden also improved, including the Gastrointestinal Symptom Rating Scale total score and constipation. Important limitations remain. The sample was small, the design was unblinded, and the weights were self-measured. Notably, the intervention was bundled. There was no adjustment for multiple comparisons. These findings are hypothesis-generating but clinically relevant. Clinicians should screen early for weight loss and refer promptly for ILD-experienced dietitian support.
Commentary by Priya Balakrishnan, MD, MS, FCCP, Member of the CHEST Physician Editorial Board
CHEST® Pulmonary
Rapid Metagenomic Sequencing of Bronchoalveolar Lavage Fluid for Diagnosis of Infection in Patients With Hematologic Malignancies and Pulmonary Complications
By Matthew K. Hensley, MD, MPH, and colleagues
Timely, accurate diagnosis of pulmonary infections in patients with hematologic malignancies remains an unmet clinical need. Conventional microbiologic testing provides variable and often modest yield, underscoring the need for improved approaches. This study evaluated 16S rRNA gene sequencing (Illumina 16S-Seq) and Nanopore DNA sequencing (MinION, Oxford Nanopore Technologies) against a composite reference standard: positive bacterial culture, viral polymerase chain reaction, or fungal identification in tissue with or without culture. Limitations included uncertain disease thresholds, challenges in sequence interpretation and gene library construction, variable sample recovery, and potential effects of human DNA depletion on bacterial detection.
Although sensitivity and specificity were insufficient to replace conventional diagnostics, both methods demonstrated additive yield: 59% and 42% of samples had additional clinically relevant organisms identified with 16S and Nanopore sequencing, respectively. These findings underscore the limitations of culture-based techniques in defining microbial community structure. A climax-attack model of microbial ecology—where stable communities are disrupted by dominant pathogens—may explain infection dynamics in this population and the relevance of the additional findings from nonculture-dependent techniques.
This study shows how nonculture-based assays may complement standard diagnostics in patients with pulmonary infections who are immunocompromised. We eagerly await further refinements of these technologies.
Commentary by O’Neil Green, MBBS, MSc-C (Oxon), FCCP, Member of the CHEST Physician Editorial Board
CHEST® Critical Care
Comparison of Corticosteroid Regimens for COVID-19 and Non-COVID-19 ARDS
By Ryosuke Imai, MD, and colleagues
This dose-response network meta-analysis synthesized data from 28 randomized controlled trials involving 6,502 patients with ARDS, encompassing COVID-19 and non-COVID-19 etiologies. It demonstrates that systemic corticosteroids’ clinical benefits hinge on attaining near-maximal effective cumulative doses. Key findings reveal that the 95% effective dose (ED95)(840 mg methylprednisolone-equivalent for dexamethasone; 1,400 mg for methylprednisolone) yields significant reductions in short-term mortality and increases in ventilator-free days vs placebo. Dexamethasone data primarily drove efficacy estimates for COVID-19 ARDS at this threshold.
Hydrocortisone, evaluated at lower doses (ED95, 270 mg), exhibited modest benefits, likely due to underdosing, with log-linear modeling indicating potential gains at higher levels. Pulse-dose escalation provided no added advantage, and safety profiles were similar across agents.
These insights advance clinical practice beyond conditional endorsements in the 2024 Society of Critical Care Medicine and American Thoracic Society guidelines. By establishing evidence-based dosing for dexamethasone and methylprednisolone, this analysis supports standardized application across ARDS subtypes to improve survival. However, low evidence certainty necessitates further trials to validate these regimens and explore escalated hydrocortisone dosing.
Commentary by Jojo Alunilkummannil, MBBS, Member of the CHEST Physician Editorial Board
